﻿{"id":55,"date":"2022-02-21T10:07:00","date_gmt":"2022-02-21T04:37:00","guid":{"rendered":"https:\/\/blogs.infosys.com\/life-sciences\/?p=55"},"modified":"2022-12-09T14:55:44","modified_gmt":"2022-12-09T09:25:44","slug":"the-cloud-imperative-in-life-sciences","status":"publish","type":"post","link":"https:\/\/blogs.infosys.com\/life-sciences\/pharmaceutical-and-biotech\/the-cloud-imperative-in-life-sciences.html","title":{"rendered":"The Cloud Imperative in Life Sciences"},"content":{"rendered":"<p><strong>Cloud is no more a \u201cbuzzword\u201d. It has gradually transformed into a value-creating technology. You will find companies across industries are increasingly adopting cloud solutions. And, yes, the pandemic has only accelerated the pace.<\/strong><\/p>\n<p>Cloud is no more a \u201cbuzzword\u201d. It is now a value-creating technology. Companies across industries are increasingly adopting cloud solutions. The pharma story is no different! In fact, the pharma industry has been at a crossroads of advancing innovation and adapting to change. While doing so, it has to ensure drug supply, protect employees and adhere to compliance. These are among the several reasons why the life sciences industry is often referred to as \u201cslow to adopt technology\u201d.<\/p>\n<p>Organizations have begun to understand that cloud can fill the gaps and play a pivotal role in their transformation journey. However, this value-creating technology is usually caught within the storm of tech jargon that limits &#8220;savings&#8221; and &#8220;security&#8221; as the only business benefits. In reality, the benefits of cloud transformation go way beyond that!<\/p>\n<h2>CLOUD OPENS THE DOORS TO A MULTITUDE OF OPPORTUNITIES<\/h2>\n<p>If you take a look back, roughly 2 years ago, it was the onset of COVID-19 that led to sudden discussions around scalability, resilience, infra to handle gigantic amounts of data, and the need to find new ways of care delivery. For instance, it took uncertain times for us to finally realize the huge benefits and convenience of virtual care or telehealth that has been around for years. Telehealth witnessed a sudden rise in adoption by patients as well as increasing acceptance by healthcare providers and other stakeholders. Now the cloud is more than a technology solution, it is also a marketplace. Big techs like Google, Microsoft et al. are aware of this. For the pharma industry, especially, it could help open a myriad of opportunities including these:<\/p>\n<h3>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Modernizing Clinical Trials<\/h3>\n<p>The ball is already set rolling. Organizations have begun conducting virtual clinical trials that are not restricted to a specific area or race. More diverse volunteers mean better results. Cloud can store the gigantic amounts of data generated, which boosts the capacity to get relevant volunteers, optimize processes, and improve the identification and monitoring of eligible patients. Going by a recent study, the market size of global virtual clinical trials is likely to touch USD 12.9 billion by 2030 [1].<\/p>\n<p>The reason is straightforward &#8211; healthcare cloud services efficiently and quickly randomize data. This reduces and even eliminates the possibility that someone will be able to identify the volunteer. By moving trails related data to cloud-based technology allows for more collaboration across the pharma ecosystem. This can also help bring together real patients who are willing to volunteer without compromising security.<\/p>\n<h3>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Paving the way for SaaS Solutions<\/h3>\n<p>In the last few years, there has been no dearth of smart wearables. You may have noticed that many people \u2013 fitness enthusiasts or not \u2013 track daily activities using smartwatches or other trackers. This wider acceptance along with SaaS (software as a service) medical devices have paved the way for patient-centric wearable technologies in clinical trials.<\/p>\n<p>With this, healthcare personnel can offer today\u2019s modern and evolved patients or rather consumers a more personalized therapy before, during as well as after treatment. Cloud ensures that information gathered by these wearable sensors is accessible anytime, anywhere. This provides patients with precise instructions outside of the clinic. SaaS medical gadgets will accelerate digital therapeutics.<\/p>\n<h3>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Handling complex operations with electronic records<\/h3>\n<p>Another aspect, where cloud transformation can make an enormous difference is in claims administration and processing. It can get way too complex to manage the voluminous data from healthcare providers, government officials, insurers, labs, pharmaceutical firms, and others. Electronic health records (EHR) or storing data in the cloud reduces the time spent by personnel in managing claims, thereby increasing healthcare service efficiency. This also means, during emergency, physicians or administrative personnel can instantly retrieve the required patient data. A holistic view of the information combined with emerging technologies like artificial intelligence (AI), machine learning (ML) and advanced analytics can help derive real-time actionable insights. Using these insights, stakeholders can take the next best decision, eventually reducing costs and delivering outcome-based patient care.<\/p>\n<h2>EMPOWERING THE ENTIRE VALUE CHAIN<\/h2>\n<p>With patients or rather consumers actively participating in their treatment and willing to share information, the amount of data created, stored and analyzed is likely to grow exponentially. Cloud can:<\/p>\n<ul>\n<li><em>Keep up with the need for scale and speed across the pharma value chain<\/em><\/li>\n<li><em>Power a data-driven approach to create a technique for the whole pharma life cycle<\/em><\/li>\n<li><em>Ensure flexibility, quick deployment and personalized patient experiences<\/em><\/li>\n<\/ul>\n<p>Be it trials, drug discovery, R&amp;D or manufacturing, cloud solutions powered by AI, ML and other technologies can ensure operational efficiencies and compliance across the value chain.<\/p>\n<h2>THE WAY FORWARD<\/h2>\n<p>The cloud is already seen as a disruptive force within the pharma industry. Going by reports, the healthcare cloud computing market may surpass $79bn by 2027 [2].\u00a0 Hyperscalers like Microsoft, Amazon and Google have already started making strides in the healthcare and life sciences industry. We\u2019ve also been seeing wearables and apps from the ever-growing startup space as well as big tech players like Apple.<\/p>\n<p>For traditional pharma and healthcare organizations, building resilience throughout the enterprise is essential to not just survive but thrive in the new normal. But, this cannot be done in silos!<\/p>\n<p>While technology is an enabler, collaborations will ensure true success. All stakeholders \u2013 providers, employers, insurers, clinicians, technology providers, government and consumers \u2013 must work together to ensure better, outcome-centric patient experiences.<\/p>\n<p>__________________________________________________________________________<\/p>\n<p>Source<\/p>\n<p>[1]<a href=\"https:\/\/www.researchandmarkets.com\/reports\/5415490\/virtual-clinical-trials-market-size-share-and?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=jnv67t&amp;utm_campaign=1652986+-+Global+Virtual+Clinical+Trials+Market+2022-2030%3a+Clinical+Ink%2c+IQVIA+Holdings%2c+ICON%2c+LEO+Innovation+Lab+and+Oracle+Dominate+Market+Among+Others&amp;utm_exec=shbe20prd\">Research and Markets, Global Virtual Clinical Trials Market 2022-2030, Jan 2022<\/a><\/p>\n<p>[2]<a href=\"https:\/\/www.gminsights.com\/pressrelease\/healthcare-cloud-computing-market\">Global Market Insights, Healthcare Cloud Computing Market worth over $79bn by 2027, Feb 2021<\/a><\/p>\n<p>__________________________________________________________________________<\/p>\n<p>Originally published at www.linkedIn.com<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cloud is no more a \u201cbuzzword\u201d. It has gradually transformed into a value-creating technology. [&hellip;]<\/p>\n","protected":false},"author":225,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[8,5,6,7],"coauthors":[4],"class_list":["post-55","post","type-post","status-publish","format-standard","hentry","category-pharmaceutical-and-biotech","tag-clinicaltrials","tag-cloud","tag-lifesciences","tag-pharmaindustry"],"acf":[],"_links":{"self":[{"href":"https:\/\/blogs.infosys.com\/life-sciences\/wp-json\/wp\/v2\/posts\/55","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.infosys.com\/life-sciences\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.infosys.com\/life-sciences\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.infosys.com\/life-sciences\/wp-json\/wp\/v2\/users\/225"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.infosys.com\/life-sciences\/wp-json\/wp\/v2\/comments?post=55"}],"version-history":[{"count":12,"href":"https:\/\/blogs.infosys.com\/life-sciences\/wp-json\/wp\/v2\/posts\/55\/revisions"}],"predecessor-version":[{"id":130,"href":"https:\/\/blogs.infosys.com\/life-sciences\/wp-json\/wp\/v2\/posts\/55\/revisions\/130"}],"wp:attachment":[{"href":"https:\/\/blogs.infosys.com\/life-sciences\/wp-json\/wp\/v2\/media?parent=55"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.infosys.com\/life-sciences\/wp-json\/wp\/v2\/categories?post=55"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.infosys.com\/life-sciences\/wp-json\/wp\/v2\/tags?post=55"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.infosys.com\/life-sciences\/wp-json\/wp\/v2\/coauthors?post=55"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}